Cema-cel also has breakthrough therapy designation for 3rd line r/r LBCL. This was all public information prior to the licensing of Azer-cel. 3rd line treatment is obviously not a large market, so they have attacked front-line consolidation. Very smart commercialization strategy utilizing the advantages of allogeneic.
You are also correct re patient recruitment numbers and timelines, Bav. Nice work.
https://crisprmedicinenews.com/news/allogene-therapeutics-activates-first-clinical-sites-for-pivotal-phase-2-trial-of-cema-cel/#:~:text=In%20June%202022%2C%20the%20FDA,LBCL%20launched%20in%20June%202024.
- Forums
- ASX - By Stock
- IMU
- Media Thread
IMU
imugene limited
Add to My Watchlist
18.2%
!
1.3¢

Media Thread, page-17925
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
1.3¢ |
Change
0.002(18.2%) |
Mkt cap ! $97.07M |
Open | High | Low | Value | Volume |
1.2¢ | 1.4¢ | 1.1¢ | $625.7K | 50.56M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
20 | 5795292 | 1.2¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
1.3¢ | 3258567 | 9 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
18 | 5735292 | 0.012 |
35 | 10497532 | 0.011 |
118 | 35980571 | 0.010 |
37 | 19431668 | 0.009 |
13 | 4220748 | 0.008 |
Price($) | Vol. | No. |
---|---|---|
0.013 | 3078567 | 8 |
0.014 | 10063029 | 39 |
0.015 | 6593187 | 20 |
0.016 | 6224494 | 27 |
0.017 | 7006978 | 10 |
Last trade - 16.10pm 27/06/2025 (20 minute delay) ? |
Featured News
IMU (ASX) Chart |
The Watchlist
PAR
PARADIGM BIOPHARMACEUTICALS LIMITED..
Paul Rennie, MD & Founder
Paul Rennie
MD & Founder
SPONSORED BY The Market Online